According to the Associated Press, when India launched its internal immunization program in January, India was happy with its success and assured the country that the vaccine export would be carried out in keeping with the internal immunization program. However, with the pace at which their vaccines are being approved worldwide and the growing demand for them outside the home, the South Asian country is falling into disrepair. Apart from that, two major vaccine manufacturers in India, Serum Institute and Bharat Biotech, failed to produce adequate quantities of vaccines.
In order to bridge the gap between rich and poor countries, the US-German partnership Pfizer and Bioentech have pledged to supply 200 million doses of vaccine to low- and middle-income countries.